| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 09/08/2000 | CA2361164A1 Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity |
| 09/06/2000 | EP1033366A2 Amide derivatives useful as Neuropeptide Y (NPY) antagonists |
| 09/06/2000 | EP1032682A1 Desaturase genes and their use |
| 09/06/2000 | EP1032667A2 A33-related antigens and their pharmacological uses |
| 09/06/2000 | EP1032656A1 Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor |
| 09/06/2000 | EP1032575A1 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
| 09/06/2000 | EP1032571A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists |
| 09/06/2000 | EP1032561A1 Substituted oximes as neurokinin antagonists |
| 09/06/2000 | EP1032555A1 Cyclic amino acids and derivatives thereof useful as pharmaceutical agents |
| 09/06/2000 | EP1032415A2 Composition for the treatment of allergic conditions having cysteine and serine proteinase inhibitory activity |
| 09/06/2000 | EP1032412A1 Use of heparin-binding protein for the modulation or prophylaxis of apoptosis of mammalian cells |
| 09/06/2000 | EP1032396A1 New composition of matter |
| 09/06/2000 | EP1032394A1 Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour |
| 09/06/2000 | EP1032393A1 QUINOLINE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS |
| 09/06/2000 | EP1032385A1 Use of substituted diphenyl indanone, indane and indole compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cellproliferation, diarrhe and scours |
| 09/06/2000 | EP1032377A1 Substituted 2-aminoacetamides and the use thereof |
| 09/06/2000 | EP0882066B1 Peptide derivatives |
| 09/06/2000 | EP0785947B1 Peptides endowed with antiinflammatory activity |
| 09/06/2000 | EP0719145B1 Nitric oxide donor composition for treatment of anal disorders |
| 09/06/2000 | EP0697864B1 Use of ferrioxamine b in the treatment os septic shock |
| 09/06/2000 | EP0665844B1 Substituted benzylaminoquinuclidines as substance p antagonists |
| 09/06/2000 | CN1265675A Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265674A 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265673A Dipeptide compounds which inhibit leukocyte adhesion medicated by VLA-4 |
| 09/06/2000 | CN1265670A Dipeptide and related compounds which inhibit leukocyte adhesion medicated by VLA-4 |
| 09/06/2000 | CN1265669A Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265668A Subtsituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265657A Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265652A 2-acrylaminopropanamines as tachykinin receptor antagonists |
| 09/06/2000 | CN1265649A Indole derivatives as MCP-1 receptor antagonists |
| 09/06/2000 | CN1265647A Acrylic metalloprotease inhibitor |
| 09/06/2000 | CN1265645A Urokinase inhibitors |
| 09/06/2000 | CN1265591A Coumpound |
| 09/06/2000 | CN1265590A Substituted alkanohydroxamic acid and method of reducing TNF 'alpha' levels |
| 09/06/2000 | CN1265587A Fast-acting analgesic |
| 09/06/2000 | CN1265317A Hantongling capsule for treatment of wind-cold and wind-dampness syndrome |
| 09/06/2000 | CN1265309A Medicine for rheumatism and aploplexy and its preparation |
| 09/06/2000 | CN1056151C 17-deoxycorticosteroid-21-(O)-carboxylic esters, process for their preparation and pharmaceuticals containing these compounds |
| 09/06/2000 | CN1056141C 哌嗪衍生物 Piperazine derivatives |
| 09/05/2000 | US6114568 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors |
| 09/05/2000 | US6114517 Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules |
| 09/05/2000 | US6114389 Use of a pharmaceutically acceptable oxalate derivative for the treatment of skin conditions |
| 09/05/2000 | US6114388 Monofunctional and/or polyfunctional polylysine conjuages |
| 09/05/2000 | US6114385 Administering l-carnitine, acyl l-carnitine derivatives or pharmacologically acceptable salts thereof for prophylaxis of diseases or treatment of cellular disorders caused by high levels of ceramide |
| 09/05/2000 | US6114377 For topical application, comprising an antimicrobial effective amount of 3-furancarboxylic acid combined with 2-furancarboxylic acid and optionally ferulic acid as an antiirritant; free of preservatives |
| 09/05/2000 | US6114372 Matrix metalloproteinase (mmp); tumor necrosis factor(tnf); compounds such as n2-((2s)-acetylmercapto)acetyl-5-phthalimidopentanoyl)-n1-((4 -methoxybenzene)sulphonyl)-n1-(phenylmethyl)hydrazine |
| 09/05/2000 | US6114367 Such as 3-(3-cyclopentyloxy-4-methoxy)phenyl-2-isoxazoline-5-hydroxamic acid; treating sepsis, septic shock, inflammatory bowel disease, tuberculosis, graft versus host disease or cachexia associated with aids or cancer in a mammal |
| 09/05/2000 | US6114361 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| 09/05/2000 | US6114360 Pyrrole compounds |
| 09/05/2000 | US6114358 Thrombin inhibitors |
| 09/05/2000 | US6114338 Heterocyclic compounds |
| 09/05/2000 | US6114328 Isoxazoline and isoxazole fibrogen receptor antagonists |
| 09/05/2000 | US6114318 17β-(2-oxo-tetrahydrofuranyl)-thio- substituted androstane derivatives |
| 09/05/2000 | US6114317 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 09/05/2000 | US6114316 Combination of bisphosphonate and tetracycline |
| 09/05/2000 | US6113906 Water-soluble non-antigenic polymer linkable to biologically active material |
| 09/05/2000 | US6113899 Antagonists of chaperonin 10 |
| 09/05/2000 | US6113898 Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| 09/05/2000 | CA2001160C Pyridine derivatives |
| 08/31/2000 | WO2000050641A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION |
| 08/31/2000 | WO2000050639A2 Gene sequence variations with utility in determining the treatment of disease |
| 08/31/2000 | WO2000050633A1 Method for cloning signal transduction intermediates |
| 08/31/2000 | WO2000050577A1 Drug design based on the structure of lta4 hydrolase |
| 08/31/2000 | WO2000050562A2 Dna encoding snorf25 receptor |
| 08/31/2000 | WO2000050431A1 Platinum (ii) compounds |
| 08/31/2000 | WO2000050429A1 Drugs containing phosphoric acid derivatives as the active ingredient |
| 08/31/2000 | WO2000050425A1 Polycyclo heterocyclic derivatives as antiinflammatory agents |
| 08/31/2000 | WO2000050418A1 Heterocyclic benzenesulphonamide compounds as bradykinine antagonists |
| 08/31/2000 | WO2000050408A1 Pyridazin-3-one derivatives and medicines containing the same |
| 08/31/2000 | WO2000050401A1 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists |
| 08/31/2000 | WO2000050400A1 2-aminopyridines containing fused ring substituents |
| 08/31/2000 | WO2000050398A2 Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
| 08/31/2000 | WO2000050395A1 Sulfonamide-containing indole compounds |
| 08/31/2000 | WO2000050079A1 Tumor necrosis factor antagonists for the treatment of neurological disorders |
| 08/31/2000 | WO2000050028A1 Compositions for the treatment of pain |
| 08/31/2000 | WO2000033667A3 Bioflavonoids, anthocyanins and phenol compounds from cherries as antioxidants |
| 08/31/2000 | WO2000012074A3 Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| 08/31/2000 | WO2000001375A3 Calcium channel blockers |
| 08/31/2000 | DE10008042A1 Neurokinin-1-Rezeptorantagonisten Neurokinin-1 receptor antagonists |
| 08/31/2000 | CA2364712A1 Platinum (ii) compounds |
| 08/31/2000 | CA2364130A1 Tumor necrosis factor antagonists for the treatment of neurological disorders |
| 08/31/2000 | CA2362906A1 Dna encoding snorf25 receptor |
| 08/31/2000 | CA2362533A1 Gene sequence variations with utility in determining the treatment of disease |
| 08/31/2000 | CA2362099A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 08/31/2000 | CA2360934A1 Polycyclo heterocyclic derivatives as antiinflammatory agents |
| 08/30/2000 | EP1031353A1 Antimycotic compositions |
| 08/30/2000 | EP1031347A1 Transnasal transport/immunisation with highly adaptable carriers |
| 08/30/2000 | EP1030851A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 08/30/2000 | EP1030845A1 Heterocyclic compounds having mmp and tnf inhibitory activity |
| 08/30/2000 | EP1030842A1 Metalloproteinase inhibitors |
| 08/30/2000 | EP1030840A1 Cyclic amine derivatives and their use as drugs |
| 08/30/2000 | EP1030836A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 08/30/2000 | EP1030835A2 Urea derivatives and their use as integrin inhibitors |
| 08/30/2000 | EP1030662A2 Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists |
| 08/30/2000 | EP1030661A1 N,N-DIETHYLGLYCOLAMIDO ESTER PRODRUGS OF INDOLE sPLA 2? INHIBITORS |
| 08/30/2000 | EP1030660A1 A transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonium salt, and the manufacturing method thereof |
| 08/30/2000 | EP0831912A4 Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 08/30/2000 | EP0799198B1 Anti-inflammatory compounds |
| 08/30/2000 | EP0642348B1 Antibiotic cryptdin peptides and methods of their use |
| 08/30/2000 | EP0631501B1 Glycosylation-mediated inhibition of factor x |